Epidermal growth factor receptor tyrosine kinase inhibitor-resistant disease.
about
Targeted therapies and immunotherapy in non-small-cell lung cancerIntrinsic resistance to EGFR tyrosine kinase inhibitors in advanced non-small-cell lung cancer with activating EGFR mutationsSomatic DNA mutation analysis in targeted therapy of solid tumoursThe Evolution of Therapies in Non-Small Cell Lung CancerTransformation from non-small-cell lung cancer to small-cell lung cancer: molecular drivers and cells of originManagement of acquired resistance to epidermal growth factor receptor kinase inhibitors in patients with advanced non-small cell lung cancerHeterogeneity of epidermal growth factor receptor signalling networks in glioblastomaA small molecule with anticancer and antimetastatic activities induces rapid mitochondrial-associated necrosis in breast cancer.Discovery of a mutant-selective covalent inhibitor of EGFR that overcomes T790M-mediated resistance in NSCLC.A systematic profile of clinical inhibitors responsive to EGFR somatic amino acid mutations in lung cancer: implication for the molecular mechanism of drug resistance and sensitivity.Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints.Histopathological transformation to small-cell lung carcinoma in non-small cell lung carcinoma tumorsNext-generation EGFR/HER tyrosine kinase inhibitors for the treatment of patients with non-small-cell lung cancer harboring EGFR mutations: a review of the evidenceRe-Treatment with EGFR-TKIs in NSCLC Patients Who Developed Acquired ResistanceNF-κB-activating complex engaged in response to EGFR oncogene inhibition drives tumor cell survival and residual disease in lung cancerHereditary lung cancer syndrome targets never smokers with germline EGFR gene T790M mutationsDrug resistance missense mutations in cancer are subject to evolutionary constraintsDistinct clinical outcomes of non-small cell lung cancer patients with epidermal growth factor receptor (EGFR) mutations treated with EGFR tyrosine kinase inhibitors: non-responders versus respondersEpidermal growth factor receptor (EGFR) mutations in lung cancer: preclinical and clinical data.Durable Response of Spinal Chordoma to Combined Inhibition of IGF-1R and EGFRBeyond histology: translating tumor genotypes into clinically effective targeted therapies.Systems biology approaches to develop innovative strategies for lung cancer therapy.The quest to overcome resistance to EGFR-targeted therapies in cancer.Reversing EGFR Mediated Immunoescape by Targeted Monoclonal Antibody TherapyTriplet therapy with afatinib, cetuximab, and bevacizumab induces deep remission in lung cancer cells harboring EGFR T790M in vivo.Acquired resistance of EGFR-mutant lung adenocarcinomas to afatinib plus cetuximab is associated with activation of mTORC1.U.S. Food and Drug Administration approval summary: Erlotinib for the first-line treatment of metastatic non-small cell lung cancer with epidermal growth factor receptor exon 19 deletions or exon 21 (L858R) substitution mutations.Glucose metabolism-targeted therapy and withaferin A are effective for epidermal growth factor receptor tyrosine kinase inhibitor-induced drug-tolerant persisters.KPT-330 has antitumour activity against non-small cell lung cancer.Drug resistance to molecular targeted therapy and its consequences for treatment decisions in non-small-cell lung cancer.Rapamycin prevents the development and progression of mutant epidermal growth factor receptor lung tumors with the acquired resistance mutation T790M.The potential role of extracellular regulatory kinase in the survival of patients with early stage adenocarcinomaClinical significance of BIM deletion polymorphism in non-small-cell lung cancer with epidermal growth factor receptor mutation.Bioinformatics-driven discovery of rational combination for overcoming EGFR-mutant lung cancer resistance to EGFR therapy.EGFR phosphorylation of DCBLD2 recruits TRAF6 and stimulates AKT-promoted tumorigenesis.Dual inhibition of EGFR with afatinib and cetuximab in kinase inhibitor-resistant EGFR-mutant lung cancer with and without T790M mutationsNovel agents in development for advanced non-small cell lung cancer.Resistance to ROS1 inhibition mediated by EGFR pathway activation in non-small cell lung cancerPD-1/PD-L1 pathway in non-small-cell lung cancer and its relation with EGFR mutation.Optimizing the sequence of anti-EGFR-targeted therapy in EGFR-mutant lung cancer.
P2860
Q26738986-1239794C-3076-4804-90F8-35905CF07328Q26744339-CB4B5135-5992-4E92-B918-0DCBD3FBA909Q26770324-00922AD2-FD7F-4F2A-9A89-AE07D099A469Q26786932-B6B084C8-84DA-421E-BEA9-3ACBDF1711BEQ26826437-D3A1DC70-A8E3-4D64-8FFC-62D3BCDE11CAQ26865779-868FBCD9-6A65-4559-997B-E9DF2F923836Q27013006-D21B23E6-2120-493A-806E-B07154BFD2FEQ27345313-9066BD0D-5D6C-468A-A4A3-AA708AE4CE76Q27852553-9E33A374-BD6D-4536-94F8-CEF18668CBFEQ27852979-45527A9F-9386-4D71-A914-AEE9906AF714Q27853339-83260EED-83A5-4074-A3ED-EE7D686E0E88Q28077504-AB927415-7815-4E5E-B93E-844A296AB41FQ28079320-904C66FA-83DE-4494-A961-FD8DBA44D2C3Q28083239-8111D413-2479-4069-ADEF-E34B5408BF0BQ28259999-15294ED3-3033-47D6-ADD6-85B0F9DD31C2Q28384015-BF6EEF87-A387-44EA-88C2-DB08BD5B7754Q28537830-E9BB4C18-0465-4941-B008-7A4C5DA6C4D4Q28537922-BCA96D2C-D106-4883-8260-42F280CF5C6AQ30850656-E4BB9873-9AA6-4FE0-A589-4F6426E905C5Q33276057-40675C85-C0BF-4624-8853-5EFB83840274Q33560928-EDD3D947-BA6F-43B7-A5DE-5AAA3594E666Q33720233-DA73F124-AB14-431F-8932-4BB85D5844ECQ33725976-9014D20A-FA61-4DE9-989F-2E03A2A825AEQ33736664-FBBB8EA9-038E-4EB5-AC39-42D3E1820D73Q33787355-EFF7F648-E176-41A4-8BE1-95E29A3D55EEQ33819404-D6545B55-4DED-4EFD-A0D6-A8F8DB7EA6D3Q33829794-A23B3301-8536-4E5F-ADDB-C623048A3DD9Q33873274-EE066C50-DE68-4CA6-BAF4-11B7B82B5720Q33918079-8E6F1F81-8CC3-4EF6-9EC4-F7CBEB6C6B00Q33938441-A5EB044F-EDB6-4A87-9B4B-2DFA5D39BE68Q33948614-AED0D407-1830-4189-990D-46B2AE10640AQ33995206-FB125A3A-71A0-4AD4-B2DA-1D396B3B0AC6Q34041761-1DC48842-BAC9-432F-B31E-122BEA63AF85Q34103108-731AE594-3B21-4558-A138-BC4DD16028B9Q34117589-0758C81D-93F6-40B1-869D-40AA00260664Q34135471-14C993C7-5874-40BC-942C-067AE08863D6Q34389263-4E24D015-4230-4BC8-B1EA-0948306C2E76Q34392733-167C0CC9-15BF-49FA-BBB5-2FA6A977B42BQ34996125-EBCA4A5B-301C-45BC-9A93-B3C8B45D4129Q35112467-1A0C2C2A-DFAD-4C65-A44D-B995BB9187FB
P2860
Epidermal growth factor receptor tyrosine kinase inhibitor-resistant disease.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
Epidermal growth factor receptor tyrosine kinase inhibitor-resistant disease.
@ast
Epidermal growth factor receptor tyrosine kinase inhibitor-resistant disease.
@en
type
label
Epidermal growth factor receptor tyrosine kinase inhibitor-resistant disease.
@ast
Epidermal growth factor receptor tyrosine kinase inhibitor-resistant disease.
@en
prefLabel
Epidermal growth factor receptor tyrosine kinase inhibitor-resistant disease.
@ast
Epidermal growth factor receptor tyrosine kinase inhibitor-resistant disease.
@en
P2093
P2860
P356
P1476
Epidermal growth factor receptor tyrosine kinase inhibitor-resistant disease.
@en
P2093
Franziska Michor
Kadoaki Ohashi
Yosef E Maruvka
P2860
P304
P356
10.1200/JCO.2012.43.3912
P407
P50
P577
2013-02-11T00:00:00Z